Equity Research Biotechnology

Should You Buy Caris Life Sciences, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Caris Life Sciences, Inc. (CAI) carries a solid Quality of Company rating of 6.0/10. Trading at $28.50, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 1 CirclFi valuation models project upside for Caris Life Sciences, Inc. (CAI) at $28.50 — the model consensus leans bearish, with a Quality Score of 6.0/10 and Value-Trap risk of 30/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 6.0/10 — Moderate — mixed signals
  • Value Trap Risk: 30/100 — Low — manageable risk
  • Fair Value Range: $2.13 – $2.13 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

6.0 /10

Moderate — mixed signals

Value Trap Risk

30 /100
Low

Low — manageable risk

Model Consensus

1 /13
Active Models

Avg. confidence: 38%

What Is the Investment Case for Caris Life Sciences, Inc. (CAI) in 2026?

What Is the Bull Case vs the Bear Case for Caris Life Sciences, Inc. (CAI)?

Bull case versus bear case for Caris Life Sciences, Inc. (CAI) at $28.50, derived from 1 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $2.13 target (-92.5%)
No active model projects meaningful upside for CAI at $28.50. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $2.13 (-92.5%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: competitive pipeline overlap represents a meaningful risk for Caris Life Sciences, Inc. and its Biotechnology peers.

How Does CAI Compare to Its Biotechnology Peers?

ALEC Alector, Inc.
6.0
KURA Kura Oncology, Inc.
6.0
PRQR ProQR Therapeutics N
6.0
RANI Rani Therapeutics Ho
6.0
VALN Valneva SE
6.0
ISCO International Stem C
6.0
ACIU AC Immune SA
5.0
SGMT Sagimet Biosciences
4.5

Valuation data pages: ALEC · KURA · PRQR · RANI · VALN · ISCO · ACIU · SGMT · EVGN · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like CAI on Quality?

Closest companies to CAI’s Quality of Company score of 6.0/10, across all industries.

Which Biotechnology Screens Does CAI Appear In?

Why Do CirclFi’s 1 Models Disagree on CAI?

Spread

0%

Fair Value Range

$2.13 – $2.13

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Regime Cross

$2.13 (-92.5%)

Most Bearish

Regime Cross

$2.13 (-92.5%)

What Are the Biggest Risks of Buying CAI Stock?

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CAI Data Page →

So Is Caris Life Sciences, Inc. (CAI) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Caris Life Sciences, Inc. at $28.50. 1/1 models flag overvaluation, median fair value sits at $2.13 (-92.5%), and the risk-reward profile appears unfavorable. Quality at 6.0/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Caris Life Sciences, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About CAI Stock?

Should I buy CAI stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for CAI at $28.50. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Caris Life Sciences, Inc.?

Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does CAI compare to its competitors?

Among Biotechnology peers, CAI holds a Quality Score of 6.0/10. Comparable companies include ALEC (QOC 6.0), KURA (QOC 6.0), PRQR (QOC 6.0). The relative ranking helps investors identify whether CAI offers better fundamental quality than alternatives in the same sector.

Is CAI a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CAI's Quality Score of 6.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy CAI at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $2.13 to $2.13. At $28.50, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CAI.

View CAI Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →